Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	81	74	1,050	890	278	78
Market Cap Growth	-83.70%	-92.92%	17.97%	220.59%	254.99%	-74.14%
Enterprise Value	-47	-45	833	700	235	4
PE Ratio	-	-0.84	-12.08	-9.80	-5.44	-0.48
PS Ratio	2.61	2.38	35.30	131.67	42.84	18.51
PB Ratio	0.57	0.47	5.32	4.51	7.38	1.12
P/FCF Ratio	-1.19	-0.93	-15.41	-16.98	-7.10	-0.80
P/OCF Ratio	-1.21	-0.95	-15.54	-17.08	-7.19	-0.81
EV/Sales Ratio	-1.29	-1.43	28.01	103.46	36.23	0.91
EV/EBITDA Ratio	0.52	0.51	-9.68	-7.78	-4.71	-0.02
EV/EBIT Ratio	0.52	0.50	-9.59	-7.70	-4.59	-0.02
EV/FCF Ratio	0.55	0.56	-12.22	-13.34	-6.01	-0.04
Debt / Equity Ratio	-	-	0.00	0.00	0.30	0.01
Debt / EBITDA Ratio	-	-	-0.01	-0.01	-0.23	0.00
Debt / FCF Ratio	-	-	-0.01	-0.01	-0.29	-0.01
Quick Ratio	6.40	3.86	9.94	8.37	3.69	3.38
Current Ratio	6.74	4.16	10.56	8.94	3.87	3.74
Asset Turnover	0.15	0.14	0.12	0.03	0.08	0.02
Return on Equity (ROE)	-48.60%	-52.80%	-41.70%	-47.80%	-109.70%	-136.00%
Return on Assets (ROA)	-37.40%	-40.20%	-33.90%	-37.70%	-62.90%	-88.50%
Return on Capital (ROIC)	-77.22%	-79.05%	-42.94%	-33.02%	-99.21%	-156.38%
Earnings Yield	-95.10%	-118.96%	-8.27%	-10.21%	-18.37%	-206.27%
FCF Yield	-90.69%	-107.07%	-6.49%	-5.89%	-14.08%	-125.36%
Buyback Yield / Dilution	-6.28%	-7.05%	-14.95%	-33.36%	-2.94%	-25.57%
Total Shareholder Return	-6.28%	-7.05%	-14.95%	-33.36%	-2.94%	-25.57%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).